1.The Effects of Preoperative Bronchial Arterial Infusion Chemotherapy for Stage III_A NSCLC
Liming ZOU ; Chengxin PAN ; Jiehui YANG
Journal of Chinese Physician 2001;0(01):-
Objective To evaluate preoperative bronchial atery infusion(PBAI) chemotherapy combined with surgery for patients with stage III A non-small cell lung cancer(NSCLC). Methods Seldinger procedure was used to insert the tube to bronchial artery branch which supplied blood to the tumor. The chemotherapeutic drugs were infused through the tube. After 1~3 courses of PBAI chemotherapy, the patients received operation. The patients receiving surgical treatment without PBAI chemotherapy at the corresponding period were chosen as control group. The radical resection rate and survival rate of the two groups were analyzsed. Results The response rate (CR+PR) of PBAI chemotherapy was 66.8%, and radical resection rate (90.3%) in PBAI chemotherapy group was significantly higher than that in control group(61.1%,P
2.Bronchial-pulmonary arterial sleeve resection and reconstruction in the treatment of central non-small cell lung cancer
Liming ZOU ; Chengxin PAN ; Yue JIANG ; Qiuping TU ; Yexin XU
Chinese Journal of Postgraduates of Medicine 2006;0(14):-
Objective To evaluate the indications and surgical procedure of bronchial-pulmonary arterial sleeve resection for patients with centrally located non-small cell lung cancer (NSCLC),and to prevent complications. Methods From October 1987 to December 2004, 96 cases of central NSCLC were treated with bronchial-pulmonary arterial sleeve resection and reconstruction. The results were retrospectively analyzed. Results The complication rate was 19.8%(19/96), the mortality rate in 30-day postoperation was 3.1%(3/96), the overall 1, 3, 5 year survival rates were 82.6%(76/91), 57.8%(37/64) and 39.1%(18/46) respectively. Conclusion Bronchial-pulmonary arterial sleeve resection and reconstruction in the treatment of patients with central NSCLC can not only maximize preservation of functional pulmonary parenchyma and improve the quality of life, but also provide an opportunity for those patients with poor pulmonary function to receive surgical resection of the tumor.
3.Clinical analysis of 48 patients with vaginal enlarged amputation of cervix
Siyuan ZENG ; Longyu LI ; Chengxin LI ; Kuanyong SHU ; Mei PAN ; Hanping LI ; Bing LUO ; Yunting AN ; Meirong HANG ; Yunyan WU
Chinese Journal of Obstetrics and Gynecology 2008;43(1):41-44
Objective To evaluate the feasibility and safety of vaginal enlarged amputation of cervix to treat patients with cervical cancer of stage Ⅰ a1 and cervical intraepithelial neoplasia grade Ⅲ(CIN Ⅲ)who were unfit for conization surgery.Methods From July 2002 to May 2007,patients with cervical cancer at stage Ⅰ a1,diagnosed by pathology after loop electrosurgical excision procedure(LEEP),large area CIN Ⅲ(the area of lesion≥3/4 on colposcopy),CIN Ⅲ coexisted with vaginal intraepithelial neoplasia (VAIN)in the superior segment of vagina,CIN Ⅱ-Ⅲ recurrence or with residual lesion,positive margin after conization of cervix,who wanted to preserve fertility and(or)corpus uteri were selected to receive vaginal enlarged amputation of cervix.Results Forty-eight eases including 5 with cervical cancer in stage Ⅰ a1,38 with large area CIN Ⅲ(9 with gland involvement),2 with residual lesion and 2 with positive margin after LEEP,1 recurrence after cold knife conization,received the procedure successfully.The median age was 34 years(range 27-40),median operation time was 60 minutes(range 30-100),median blood loss was 40 ml(range 5-300),and median hospital stay was 10 days(range 7-17).After follow-up 1-39 months,no patient had postoperative complications and recurrence,and all patients resumed normal menstrual cycle and sexual life.Condusion Vaginal enlarged amputation of cervix appears to be a safe and feasible procedure for patients with cervical cancer at stage Ⅰ a1 and CIN Ⅲ who are unfit for conization surgery.
4.AN INVESTIGATION ON NUTRITION AND DEVELOPMENT AND DISEASE OF CHILDREN UNDER AGE 2 IN SHANGHAI FACTORY NURSERIES
Peiyun YANG ; Meifang JU ; Jialing LING ; Lijuan YUAN ; Jue SUN ; Chengxin QIU ; Xiaofen NIU ; Jingyi TAN ; Jinwu CHEN ; Yunmin PAN
Acta Nutrimenta Sinica 1956;0(03):-
This paper is a follow-up study of 329 children in factory-run nurseries in urban Shanghai. The investigation lasted for a period of one year for each index-child, focusing on the conditions of nutrition, development and diseases of the children of various ages.Comparison between nutritionl findings and RDA of China disclosed that calorie intake of most of the index-child groups were 80-85% of RDA, the only exception being the 6-12 months group where the average calorie intake showed 90%. Protein intake of all groups was over 80% of RDA. Fe intake was lower than RDA, except for 18-month-old and over.Weight and height of the children were compared with the anthropo-metric data established in 1985 (1985 data) for Shanghai children under six years of age. It was found that the average weight and height appeared differently according to their age. Average weight of children under one year old was slightly higher than 1985 data, while average height was lower than 1985 data once the children reached 10 months old. Average weight, however, became lower than the 1985 data after the children were two years old. Over 60% of the index between 6-18 months old suffered from anemia (IDA).Accordingly, it is requested that calorie and iron intake should be supplemented.
5.Mining and Analysis of the Formulation Rules of Chinese Patent Medicine for Cold Based on 2015 Edition of Chinese Pharmacopeia(Part Ⅰ)
Haidu HONG ; Chengxin LIU ; Yu HONG ; Huiting HUANG ; Dongting LI ; Yue PAN ; Si CHEN ; Chuangrong CHEN ; Xiaohong LIU
China Pharmacy 2019;30(13):1812-1816
OBJECTIVE: To mine and analyze the formulation rules of Chinese patent medicine for cold, and to provide reference for clinical dialectical medication and R&D of new medicine for cold. METHODS: The name, dosage form, formulation, function of curing of Chinese patent medicines for cold were collected from 2015 edition of Chinese Pharmacopeia (part Ⅰ) and then input into TCM Inheritance Assistant Platform V 2.5; use frequency of TCM were counted. Apriori algorithm and association rules were used to analyze the core medicinal material combination (10% support and 0.65 confidence). New formulation combinations were extracted by unsupervised entropy hierarchical clustering method. RESULTS: A total of 130 kinds of Chinese patent medicine (196 Chinese patent medicine with the same prescription and different dosage forms) for treating cold were collected, including granules (47), pills (32), tablets (31), mixtures (31), etc. 264 medicinal materials were involved. The cold syndromes contained wind-heat syndrome, wind-cold syndrome, summer-dampness syndrome and Qi deficiency syndrome. Top 3 medicinal materials in the list of use frequency were Glycyrrhiza uralensis (45.38%), Scutellaria baicalensis (32.31%) and Platycodon grandiflorus (31.54%). There were 28 core medicinal material combinations, among which the top 3 were G. uralensis-P. grandiflorus, Mentha haplocalyx-P. grandiflorus and S. baicalensis-Forsythia suspensa. New combinations were excavated, including Nepeta cataria-P. grandiflorus-M. haplocalyx-Citrus reticulate-Folium Perillae-Citrus aurantium- Poria cocos, F. suspense-S. baicalensis-Lonicera japonica- Arctium lappa-Fermented soybean. CONCLUSIONS: This study analyzed the formulation rules of Chinese patent medicine for treating cold by using the TCM inheritance assistant platform V2.5, which can provide reference for clinical dialectical medication and R&D of new medicines for cold.